Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a finnish population

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 1, 2011, Pages 9-13

  Laitinen, Alli ^a   Niemi, Mikko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GLYCINE; ISOLEUCINE; METHIONINE; NUCLEASE; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1; PHENYLALANINE; SERINE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; FEMALE; FINLAND; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1A2 GENE; SLCO1B3 GENE; SLCO2B1 GENE;

FEMALE; FINLAND; GENE FREQUENCY; GENETIC VARIATION; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78650192441     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00605.x     Document Type: Article

References (46)

1. Hagenbuch B. Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol Ther 2010;87:39-47.
2. Franke RM, Sparreboom A. Drug transporters: recent advances and therapeutic applications. Clin Pharmacol Ther 2010;87:3-7.
3. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010;87:130-3.
4. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007;8:787-802.
5. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705.
6. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW et al. Molecular and functional characterization of organic anion transporting polypeptide cloned from human liver. Gastroenterology 1995;109:1274-82.
7. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS et al. Intestinal drug transporter expression and impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-70.
8. König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278:G156-64.
9. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000;273:251-60.
10. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120:525-33.
11. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003;306:703-8.
12. Grube M, Köck K, Oswald S, Draber K, Meissner K, Eckel L et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006;80:607-20.
13. Niessen J, Jedlitschky G, Grube M, Bien S, Schwertz H, Ohtsuki S et al. Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos 2009;37:1129-37.
14. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-71.
15. Maeda T, Takahashi K, Ohtsu N, Oguma T, Ohnishi T, Atsumi R et al. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm 2007;4:85-94.
16. Fujino H, Saito T, Ogawa S, Kojima J. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 2005;57:1305-11.
17. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793-806.
18. van Montfoort JE, Müller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ. Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther 2001;298:110-5.
19. Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 2004;1:49-56.
20. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M et al. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 2001;142:2005-12.
21. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4:1030-2.
22. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007;35:779-86.
23. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002;36:164-72.
24. Kopplow K, Letschert K, König J, Walter B, Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 2005;68:1031-8.
25. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005;33:518-23.
26. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005;280:9610-17.
27. Iida A, Saito S, Sekine A, Mishima C, Kondo K, Kitamura Y et al. Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. J Hum Genet 2001;46:668-83.
28. Letschert K, Keppler D, König J. Mutations in the SLCO1B3 gene affecting the substrate specificity of hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14:441-52.
29. Schwarz UI, Dixit SG, Leake BF, Kim RB. Identification and functional characterization of OATP1B3 allelic variants using transfected HeLa cells [abstract]. Drug Metab Rev 2006;38:237.
30. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002;302:804-13.
31. Ho RH, Leake BF, Kim RB, Wang Y. OATP2B1 allelic variants differentially transport rosuvastatin in vitro [abstract]. Drug Metab Rev 2006;38:240-241.
32. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9:19-33.
33. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 2006;62:409-15.
34. Niemi M, Arnold KA, Backman JT, Pasanen MK, Gödtel-Armbrust U, Wojnowski L et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006;16:801-8.
35. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84:457-61.
36. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86:197-203.
37. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.
38. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008;359:789-99.
39. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 2008;84:704-9.
40. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76-82.
41. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009;85:155-63.
42. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008;99:967-72.
43. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010;20:112-20.
44. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009;19:129-38.
45. Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 2006;318:521-9.
46. Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese participants. Drug Metab Pharmacokinet 2006;21:165-9.